Oculis Holding AG

OCSPhase 3

Oculis is dedicated to improving the sight and lives of patients through innovative topical ophthalmic therapies. Its lead asset, OCS-01, is a novel topical formulation of dexamethasone in Phase 3 development for DME and inflammation following cataract surgery, potentially offering a non-invasive alternative to injections. The company's strategy is built on its proprietary SNAP technology platform, which enables efficient drug delivery across ocular barriers, and it has strengthened its position through a Nasdaq IPO and key clinical advancements.

Market Cap

$1.4B

Employees

50-100

Focus

Biotech

OCS · Stock Price

USD 24.86+15.12 (+155.24%)

Historical price data

AI Company Overview

Technology Platform

Oculis SNAP (Self-assembling Nanoparticle) technology enhances topical drug delivery to both front and back of the eye. The Oculis Solubilizing Particle (OSP) technology improves solubility and bioavailability of poorly soluble drugs in eye drops.

Pipeline Snapshot

9 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
Dexamethasone ophthalmic suspension (OCS-01) + Vehicle	Diabetic Macular Edema	Phase 3
Dexamethasone Ophthalmic Suspension	Inflammation Eye	Phase 3
OCS-01 + Vehicle	Inflammation Eye Pain	Phase 3
Dexamethasone ophthalmic suspension (OCS-01) + Vehicle	Diabetic Macular Edema	Phase 2/3
licaminlimab	Dry Eye Disease	Phase 2

Funding History

Total raised: $124M

IPO$35MUndisclosedMar 15, 2023

Series B$57MNovartis Venture FundMar 15, 2021

Series A$32MNovo HoldingsJun 15, 2019

Opportunities

The primary growth opportunity lies in successfully commercializing OCS-01 as the first topical therapy for DME, capturing a multi-billion dollar market.

Additionally, expanding the SNAP platform to deliver other therapeutic classes (e.g., anti-VEGF agents) and securing strategic partnerships for global commercialization present significant avenues for growth.

Risk Factors

Key risks include clinical trial failures for lead assets OCS-01 and OCS-02, regulatory hurdles for approval, intense competition from established injection therapies in DME, and the company's current pre-revenue status requiring continued capital raises, which may lead to shareholder dilution.

Competitive Landscape

Oculis faces competition from dominant anti-VEGF injections (Eylea, Lucentis) in DME and established topical steroids for inflammation. Its main differentiation is the proprietary SNAP technology enabling non-invasive treatment of retinal diseases. In Dry Eye Disease, it competes with Restasis and Xiidra, differentiating via its novel topical anti-TNFα mechanism.

Publications

Pipeline